DS
ECYT

DRW Securities’s Endocyte, Inc. Common Stock ECYT Stock Holding History

DRW Securities’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-11,000
Closed -$16K – 480
2017
Q3 		$16K Hold
11,000
– – ﹤0.01% 64
2017
Q2 		$17K Hold
11,000
– – ﹤0.01% 71
2017
Q1 		$28K Buy
+11,000
New +$25.4K ﹤0.01% 71
2016
Q2 		– Sell
-30,017
Closed -$93K – 104
2016
Q1 		$93K Buy
+30,017
New +$98K 0.01% 74

Other funds holding ECYT

PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DRW Securities's ECYT Position: Q4 2017 in Review

DRW Securities sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2017, closing a stake of 11,000 shares — an estimated $16K sold.

DRW Securities first reported a position in ECYT in Q1 2016 and held it in 4 quarters. The position peaked at $93K in Q1 2016. 71 funds tracked by Wall St. Rank hold ECYT as of Q4 2017.

  • DRW Securities reported no remaining Endocyte, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • DRW Securities sold 11,000 Endocyte, Inc. Common Stock shares in Q4 2017, an estimated $16K.
  • DRW Securities first reported a position in Endocyte, Inc. Common Stock in Q1 2016 and held it in 4 quarters.
  • DRW Securities's Endocyte, Inc. Common Stock position peaked at $93K in Q1 2016.
  • 71 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2017.

Based on DRW Securities's 13F filing for Q4 2017, filed 14 Feb 2018.